Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL265110 | 0.98 | — | — | |
| Hydrochloric Acid SCHEMBL560373 | 0.76 | — | — | |
| Hydrochloric Acid SCHEMBL8073418 | 0.75 | CYP1A2 (0.36) | — | |
| SCHEMBL13847959 | 0.71 | — | — | |
| SCHEMBL27764084 | 0.71 | DNM1 (0.33) | DNM1 | |
| SCHEMBL9812477 | 0.70 | DNM1 (0.37) | DNM1 | |
| Hydrochloric Acid SCHEMBL28310945 | 0.66 | — | — | |
| SCHEMBL2045857 | 0.65 | LMNA (0.38) | DNM1 | |
| SCHEMBL4692042 | 0.63 | TSHR (0.32) | — | |
| SCHEMBL9812486 | 0.62 | LMNA (0.35) | DNM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1883721-A | Method for modifying artificial implanter by covalent cross-linking gel | HARBIN INST OF TECHNOLOGY (CN) | 2006-12-27 | — | — | CN | claimed |
| CN-114423460-A | Tough gel-based drug delivery compositions and methods thereof | 哈佛学院院长等 | 2022-04-29 | — | — | CN | disclosed |
| WO-2020032366-A1 | IMMUNOREACTANT CARRIER | 주식회사 레모넥스 | 2020-02-13 | — | — | WO | disclosed |
| WO-2020027641-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ATOPIC DISEASES | 주식회사 레모넥스 | 2020-02-06 | — | — | WO | disclosed |
| WO-2020027585-A2 | POLYPEPTIDE DELIVERY COMPOSITION | 주식회사 레모넥스 | 2020-02-06 | — | — | WO | disclosed |
| WO-2020027640-A1 | COMPOSITION FOR INHIBITING CTGF EXPRESSION | 주식회사 레모넥스 | 2020-02-06 | — | — | WO | disclosed |
| WO-2020027571-A1 | PHARMACEUTICAL COMPOSITION FOR WOUND HEALING | 주식회사 레모넥스 | 2020-02-06 | — | — | WO | disclosed |
| WO-2019022521-A9 | COMPOSITION FOR DELIVERING PHYSIOLOGICALLY ACTIVE INGREDIENTS INTO BLOOD VESSEL | 주식회사 레모넥스 | 2019-08-15 | — | — | WO | disclosed |
| US-20170166543-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | AMERICAN LIFE SCIENCE PHARMACEUTICALS INC (US) | 2017-06-15 | — | — | US | disclosed |
| US-9212192-B2 | Bicyclic carboxamide inhibitors of kinases | ABBVIE INC. (US) | 2015-12-15 | — | — | US | disclosed |
| EP-1347971-A1 | THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES | Bristol-Myers Squibb Company (US) | 2003-10-01 | — | — | EP | disclosed |
| US-6599558-B1 | Covalently bonding vinylalkoxysilane and graft polymerizing with further monomers forming hydrophilic layer; inhibiting restenosis and thrombosis | POLYBIOMED LIMITED (GB) | 2003-07-29 | — | — | US | disclosed |
| US-20030069238-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-10 | — | — | US | disclosed |
| EP-0988071-B1 | TREATING METAL SURFACES TO ENHANCE BIO-COMPATIBILITY AND/OR PHYSICAL CHARACTERISTICS | POLYBIOMED LTD (GB) | 2003-02-26 | — | — | EP | disclosed |
| WO-2002098441-A2 | METHOD OF TREATING METABOLIC DISORDERS USING NEURONATIN POLYPEPTIDES | AZIGN BIOSCIENCE A/S (DK) | 2002-12-12 | — | — | WO | disclosed |
| WO-2002050071-A1 | THIAZOLYL INHIBITORS OF TEC FAMILY TYROSINE KINASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-27 | — | — | WO | disclosed |
| EP-0988071-A2 | TREATING METAL SURFACES TO ENHANCE BIO-COMPATIBILITY AND/OR PHYSICAL CHARACTERISTICS | PolyBioMed Limited (GB) | 2000-03-29 | — | — | EP | disclosed |
| WO-1998055162-A2 | TREATING METAL SURFACES TO ENHANCE BIO-COMPATIBILITY | POLYBIOMED LIMITED (GB) | 1998-12-10 | — | — | WO | disclosed |
| US-5356433-A | Using an amino containing organosilane compound | CORDIS CORPORATION (US) | 1994-10-18 | — | — | US | disclosed |
| CN-1068110-A | dicarboxylic acid derivatives and preparation method thereof | TANABE SEIYAKU CO LTD JP (JP) | 1993-01-20 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166543-A1 | COMPOSITIONS AND METHODS FOR SYNTHESIZING (2S,3S)-TRANS-EPOXYSUCCINYL-L-LEUCYL-AMIDO-3-METHYLBUTANE ETHYL ESTER | PTMS, LTA, LPXN | DNM1 4604/4885 |
| US-20030069238-A1 | Thiazolyl inhibitors of Tec family tyrosine kinases | TEC, LCK, LTK | DNM1 3389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.